Christopher Gibson - Oct 4, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Executive Officer, Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Oct 4, 2023
Transactions value $
-$353,525
Form type
4
Date filed
10/6/2023, 06:12 PM
Previous filing
Sep 19, 2023
Next filing
Oct 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $77.5K +31.3K +3.59% $2.48 903K Oct 4, 2023 Direct F1
transaction RXRX Class A Common Stock Sale -$431K -59.8K -6.63% $7.21 843K Oct 4, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -31.3K -6.25% $0.00 469K Oct 4, 2023 Class A Common Stock 31.3K $2.48 Direct F1, F5
holding RXRX Stock Option (Right to Buy) 814K Oct 4, 2023 Class A Common Stock 0 $8.55 Direct F3
holding RXRX Stock Option (Right to Buy) 5.44K Oct 4, 2023 Class A Common Stock 0 $11.40 Direct
holding RXRX Stock Option (Right to Buy) 408K Oct 4, 2023 Class A Common Stock 0 $11.40 Direct F4
holding RXRX Class B Common Stock 6.51M Oct 4, 2023 Class A Common Stock 0 $0.00 Direct F6
holding RXRX Class B Common Stock 523K Oct 4, 2023 Class A Common Stock 0 $0.00 by LAHWRAN-3 LLC F6, F7
holding RXRX Class B Common Stock 448K Oct 4, 2023 Class A Common Stock 0 $0.00 by LAHWRAN-4 LLC F6, F8
holding RXRX Class B Common Stock 121K Oct 4, 2023 Class A Common Stock 0 $0.00 by Gibson Family Trust F6, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 22, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $7.08 to $7.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F4 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F5 The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F7 The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F8 The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F9 The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.